The FDA Just Approved a New Kind of ADHD Medication with a novel mechanism of action
On July 24, 2026, the FDA approved SIMTRIYO (centanafadine), and I think this one is worth paying attention to. It is not another stimulant, and it is not another version of the nonstimulants we already have. It works in a genuinely new way, and for a lot of my patients, that matters.
What makes this drug different
SIMTRIYO is the first medication in its class, called an NDSRI. Instead of targeting one or two brain chemicals the way most ADHD medications do, it works on three at once: norepinephrine, dopamine, and serotonin. These are the neurotransmitters most involved in attention and behavioral regulation, so increasing their availability in the right pathways is the whole point of ADHD treatment. I have not had a tool with this particular mechanism in my toolkit before.
It is approved for adults and for kids as young as 6 (as long as they weigh at least 20kg), taken once daily as an extended-release capsule. It is still classified as a CNS stimulant and will need DEA scheduling before it hits pharmacies later this year.
What the research actually showed
The approval rests on four Phase 3 trials across kids, teens, and adults, and I find the details reassuring. Patients saw meaningful symptom improvement as early as week 1, which is fast for a nonstimulant-adjacent option. A separate 52-week open-label study in adults backed this up. About half of participants who stuck with treatment saw their AISRS scores (main symptom measure for investigation studies) improve by roughly 50 percent, and that improvement held for a full year.
On safety, the most common side effects in adults were headache, decreased appetite, insomnia, nausea, dry mouth, and diarrhea. Compared to some of the long-term data we have on existing stimulants, where treatment-emergent side effects run as high as 80 to 94 percent, this trial's rate of 61 percent stands out. There is a boxed warning about suicidal ideation risk in kids ages 6 to 12, and about abuse and misuse potential, so this is not a medication without real risks to weigh. But the 52-week data showed no signs of withdrawal symptoms and no reports of euphoria, which is notable for a controlled substance.
Bottom line
ADHD is not one-size-fits-all, and neither is treatment. I am glad to have another option coming, especially one with a mechanism I have not been able to offer before. I will be watching the DEA scheduling timeline closely and will keep you posted on when it is actually available to prescribe.
References
Mattingly, G. W., Turkoglu, O., Chang, D., Ward, C., Skubiak, T., & Cutler, A. J. (2025). 52-week open-label safety and tolerability study of centanafadine sustained release in adults with attention-deficit/hyperactivity disorder. Journal of Clinical Psychopharmacology, 45(5), 454–462. https://doi.org/10.1097/JCP.0000000000002020
Otsuka Pharmaceutical Development & Commercialization, Inc. (2026, July 24). Otsuka receives FDA approval for first-in-class SIMTRIYO® (centanafadine) for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients aged 6 years and older [Press release]. Otsuka US. https://www.otsuka-us.com/otsuka-shares-fda-review-update-for-centanafadine